Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/117349
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Costs of invasive meningococcal disease: a global systematic review |
Author: | Wang, B. Santoreneos, R. Afzali, H. Giles, L. Marshall, H. |
Citation: | PharmacoEconomics, 2018; 36(10):1201-1222 |
Publisher: | Springer |
Issue Date: | 2018 |
ISSN: | 1170-7690 1179-2027 |
Statement of Responsibility: | Bing Wang, Renee Santoreneos, Hossein Afzali, Lynne Giles, Helen Marshall |
Abstract: | Background: Invasive meningococcal disease remains a public health concern because of its rapid onset and significant risk of death and long-term disability. New meningococcal serogroup B and combination serogroup ACWY vaccines are being considered for publicly funded immunization programs in many countries. Contemporary costing data associated with invasive meningococcal disease are required to inform cost-effectiveness analyses. Objective: The objective of this study was to estimate costs and resource utilization associated with acute infection and the long-term care of invasive meningococcal disease. Data Sources and Methods: PubMed, EMBASE, The Cochrane Library, health economic databases, and electronically available conference abstracts were searched. Studies reporting any costs associated with acute infection and long-term sequelae of invasive meningococcal disease in English were included. All costs were converted into purchasing power parity-adjusted estimates [international dollars (I$)] using the Campbell and Cochrane Economics Methods Group and the Evidence for Policy and Practice Information and Coordinating Centre cost converter. Results: Fourteen studies met our eligibility criteria and were included. The mean costs of acute admission ranged from I$1629 to I$50,796, with an incremental cost of I$16,378. The mean length of hospital stay was reported to be 6-18 days in multiple studies. The average costs reported for readmissions ranged from I$7905 to I$15,908. Key variables such as the presence of sequelae were associated with higher hospitalization costs and longer inpatient stay. No studies estimated direct non-healthcare costs and productivity loss. Ten studies reported only unadjusted mean values without using appropriate statistical methods for adjustment. Conclusions: Invasive meningococcal disease can result in substantial costs to healthcare systems. However, costing data on long-term follow-up and indirect costs used to populate health economic models are lacking. |
Keywords: | Humans Meningococcal Infections Hospitalization Length of Stay Models, Economic Cost-Benefit Analysis Health Care Costs Hospital Costs |
Rights: | © Springer International Publishing AG, part of Springer Nature 2018 |
DOI: | 10.1007/s40273-018-0679-5 |
Grant ID: | http://purl.org/au-research/grants/nhmrc/1084951 |
Published version: | http://dx.doi.org/10.1007/s40273-018-0679-5 |
Appears in Collections: | Aurora harvest 3 Public Health publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.